GlassScriptPhysician profile
Michael K Lai
NPI 1750318127
$43,041.23
in general payments reported to CMS, 2019-2025
61 companies · $3,731 in 2025
The $3,731 reported for 2025 was more than what 85% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $10K · 2021: $4,265 · 2022: $4,448 · 2023: $3,635 · 2024: $2,888 · 2025: $3,731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,781 · Education: $473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,780.53 |
| Education | $472.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $16,686.28 | 2019-2025 | Farxiga, Lokelma |
| Mannkind Corporation | $5,631.64 | 2019-2025 | Afrezza |
| Novo Nordisk INC | $3,106.37 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Horizon Therapeutics Plc | $2,889.24 | 2019-2023 | Tepezza |
| Amgen INC. | $2,425.51 | 2019-2025 | Evenity, Tepezza, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,391.56 | 2019-2025 | Jardiance, Synjardy |
| Abbvie INC. | $1,212.13 | 2019-2025 | |
| Lilly USA, LLC | $1,057.72 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $961.37 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $899.73 | 2022-2025 | |
| Dexcom, INC. | $448.46 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $408.70 | 2019-2022 | |
| Radius Health, INC. | $395.48 | 2019-2025 | Tymlos |
| Abbott Laboratories | $335.10 | 2019-2024 | Freestyle Libre 3 |
| Corcept Therapeutics | $334.46 | 2019-2025 | Korlym |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $304.07 | 2021-2025 | Minimed 780g |
| Novartis Pharmaceuticals Corporation | $300.07 | 2021-2025 | |
| Tandem Diabetes Care, INC. | $278.69 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Gilead Sciences, INC. | $254.02 | 2022-2024 | Epclusa |
| Beta Bionics, INC. | $231.28 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Amarin Pharma, INC. | $220.45 | 2019-2021 | |
| Insulet Corporation | $217.73 | 2021-2024 | Omnipod |
| Janssen Pharmaceuticals, INC | $212.94 | 2019-2021 | |
| Madrigal Pharmaceuticals | $187.19 | 2024-2025 | Rezdiffra, Resmetirom |
| Vistapharm, INC. | $178.22 | 2021 | |
| Companion Medical, INC. | $173.99 | 2019-2020 | |
| Esperion Therapeutics, INC. | $167.76 | 2021-2025 | Nexletol |
| Ascensia Diabetes Care US INC. | $159.11 | 2021-2025 | |
| Endo Pharmaceuticals INC. | $153.73 | 2019-2023 | Aveed |
| Antares Pharma, INC. | $146.93 | 2023-2025 | Xyosted, Nocdurna, Tlando |
| Eisai INC. | $142.24 | 2019-2021 | |
| Medtronic Minimed, INC. | $138.30 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $137.11 | 2020-2024 | Gvoke Hypopen |
| Neurocrine Biosciences, INC. | $135.96 | 2024-2025 | |
| Ibsa Pharma INC. | $134.30 | 2020-2023 | Tirosint, Licart |
| Ascendis Pharma Endocrinology INC | $129.45 | 2023-2025 | Yorvipath |
| Recordati_rare_diseases_inc. | $102.37 | 2020-2025 | Signifor Lar, Isturisa |
| Ultragenyx Pharmaceutical INC. | $87.42 | 2021-2022 | |
| Senseonics, Incorporated | $72.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $65.16 | 2020-2021 | |
| Kyowa Kirin, INC. | $60.65 | 2023-2025 | Crysvita |
| Amryt Pharma Holdings LTD | $60.26 | 2021-2023 | Mycapssa |
| Almatica Pharma LLC | $54.85 | 2025 | Teriparatide |
| Nestle Healthcare Nutrition INC. | $38.08 | 2020-2021 | |
| Grt US Holding, INC. | $25.76 | 2021 | |
| Shire North American Group INC | $22.96 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $21.53 | 2019 | |
| Aegerion Pharmaceuticals, INC. | $20.89 | 2019 | |
| Bigfoot Biomedical INC | $20.40 | 2022 | |
| Alexion Pharmaceuticals, INC. | $19.76 | 2023 | Strensiq |
| Biomarin Pharmaceutical INC. | $19.74 | 2022 | |
| Sun Pharmaceutical Industries INC. | $19.59 | 2020 | |
| Pfizer INC. | $19.01 | 2021 | |
| Sequel Med Tech, LLC | $18.07 | 2025 | Twiist |
| Halozyme INC | $17.29 | 2023 | |
| Verity Pharmaceuticals INC. | $16.80 | 2025 | Tlando |
| Alvogen INC | $15.11 | 2025 | Teriparatide |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.66 | 2023 | Xifaxan |
| Amphastar Pharmaceuticals, INC. | $14.40 | 2024 | |
| Exact Sciences Corporation | $14.12 | 2025 | The Cologuard Plus Collection Kit |
| Echosens North America, INC. | $13.06 | 2023 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.